TB Alliance press release
TB Alliance, a nonprofit drug developer, and Lupin Limited, a global pharma major, announced a global collaboration to advance the clinical development and commercialization of the investigational drug telacebec (formerly known as Q203) for the treatment of TB, leprosy, and Buruli ulcer.
Under the collaboration, TB Alliance and Lupin will work together to support the continued clinical development of telacebec and prepare for its potential future commercialization, with the shared goal of improving treatment options for people affected by these neglected diseases. TB Alliance will continue to lead development activities, while Lupin will bring its global manufacturing, regulatory, and supply expertise to help ensure broad access to telacebec.
Read the full press release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #4, 1 February 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : TB Alliance
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.